Original Articles                    

 

Shah N, Bye K, Marshall A…Boos CJ. The Effects of Apnea Training, Using Voluntary Breath Holds, on High Altitude Acclimation: Breathe-High Altitude Study. High Alt Med Biol. 2020;21(2):152-159. doi:10.1089/ham.2019.0087

 

Griffiths A, Deighton K, Shannon OM…Boos CJ et al. Appetite and energy intake responses to breakfast consumption and carbohydrate supplementation in hypoxia. Appetite. 2020;147:104564. doi:10.1016/j.appet.2019.104564.

 

Lam JH, Quah JX, Davies T, Boos CJ et al. Relationship between coronary microvascular dysfunction and left ventricular diastolic function in patients with chest pain and unobstructed coronary arteries [published online ahead of print, 2020 Aug 4]. Echocardiography. 2020;10.1111/echo.14794. doi:10.1111/echo.14794

 

Boos CJ, De Villiers N, Dyball D et al. The Relationship between Military Combat and Cardiovascular Risk: A Systematic Review and Meta-Analysis. Int J Vasc Med. 2019;2019:9849465. Published 2019 Dec 22. doi:10.1155/2019/9849465

 

Dyball D, Evans S, Boos CJ, Stevelink SAM, Fear NT. The association between PTSD and cardiovascular disease and its risk factors in male veterans of the Iraq/Afghanistan conflicts: a systematic review. Int Rev Psychiatry  2019;31(1):34-48.

 

O'Hara JP, Duckworth L, Black A, Woods DR, Mellor A, Boos C….King R. Fuel Use during Exercise at Altitude in Women with Glucose-Fructose Ingestion. Med Sci Sports Exerc. 2019;51(12):2586-2594.

 

Boos CJ, Bye K, Sevier L, Bakker-Dyos J, Woods DR, Sullivan M, Quinlan T,Mellor A. High Altitude Affects Nocturnal Non-linear Heart Rate Variability: PATCH-HA Study. Front Physiol. 2018 Apr 16;9:390.

 

Boos CJ, Bass M, O'Hara JP, Vincent E, Mellor A, Sevier L, Abdul-Razakq H, Cooke M, Barlow M, Woods DR. The relationship between anxiety and acute mountain sickness. PLoS One. 2018 Jun 21;13(6):e0197147.

 

Clarke SB, Deighton K, Newman C, Nicholson G, Gallagher L, Boos CJ, Mellor A, Woods DR, O'Hara JP. Changes in balance and joint position sense during a 12-day high altitude trek: The British Services Dhaulagiri medical research expedition. PLoS One. 2018 Jan 17;13(1):e0190919.

 

Mellor A, Bakker-Dyos J, OʼHara J … Boos CJ. Smartphone-Enabled Heart Rate Variability and Acute Mountain Sickness. Clin J Sport Med. 2018;28(1):76-81.

 

Gifford RM, Boos CJ et al. Woods DR. Recovery time and heart rate variability following extreme endurance exercise in healthy women. Physiol Rep. 2018;6(21):e13905. doi:10.14814/phy2.13905

 

Boos CJ, Lamb CM, Midwinter M et al. . The effects of acute hypoxia on tissue oxygenation and circulating alarmins in healthy adults. Physiol Res 2018;67(6):935-943.

 

Cooke M, Cruttenden R, Mellor A, BoosC et al. A pilot investigation into the effects of acute normobaric hypoxia, high altitude exposure and exercise on serum angiotensin-converting enzyme, aldosterone and cortisol. J Renin Angiotensin Aldosterone Syst. 2018;19(2):1470320318782782.

 

Stacey MMJ, Delves SK, Woods DR, … Boos CJ. Heart rate variability and plasma nephrines in the evaluation of heat acclimatisation status. Eur J Appl Physiol 2018;118(1):165-174.

 

Woods DR, O'Hara JP, Boos CJ.....Mellor A. Markers of physiological stress during exercise under conditions of normoxia, normobaric hypoxia, hypobaric hypoxia, and genuine high altitude. Eur J Appl Physiol. 2017;117(5):893-900.

 

Boos CJ, Holdsworth DA, Woods DR, O'Hara J, Brooks N, Macconnachie L, Bakker-Dyos J, Paisey J, Mellor A. Assessment of Cardiac Arrhythmias at Extreme High Altitude Using an Implantable Cardiac Monitor: REVEAL HA Study (REVEAL High Altitude). Circulation 2017;135(8):812-814.

 

Mellor A, Bakker-Dyos J, Howard M, Boos CJ et al. The British Services Dhaulagiri Medical Research Expedition 2016: a unique military and civilian research collaboration. J R Army Med Corps 2017;163(6):371-375.

 

Boos CJ, Vincent E, Mellor A, Woods DR, New C, Cruttenden R, Barlow M, Cooke M, Deighton K, Scott P, Clarke S, O'Hara J. The effect of high altitude on central blood pressure and arterial stiffness. J Hum Hypertens 2017;31(11):715-719.

 

Boos CJ, Vincent E, Mellor A, O'Hara J, Newman C, Cruttenden R, Scott P, Cooke M, Matu J, Woods DR. The Effect of Sex on Heart Rate Variability at High Altitude. Med Sci Sports Exerc. 2017;49:2562-2569.

 

Mellor A. A comparison of two methods of heart rate variability assessment at high altitude. Clin Physiol Funct Imaging 2017;37(6):582-587.

 

Matu J, O'Hara J, Hill N, Boos CJ et al. Changes in appetite, energy intake, body composition, and circulating ghrelin constituents during an incremental trekking ascent to high altitude. Eur J Appl Physiol 2017;117(9):1917-1928.

 

O'Hara JP, Woods DR, Mellor A, , ….Cooke CB, Morrison DJ, Preston T, King RF. A comparison of substrate oxidation during prolonged exercise in men at terrestrial altitude and normobaric normoxia following the co-ingestion of 13C glucose and 13C fructose. Physiol Rep. 2017 Jan;5(1). pii: e13101. doi: 10.14814/phy2.13101.

 

Nel K, Nam MCY, Anstey C, Boos CJ et al. Myocardial blood flow reserve is impaired in patients with aortic valve calcification and unobstructed epicardial coronary arteries. Int J Cardiol 2017;248:427-432.

 

Boos CJ, O'Hara JP, Mellor A, Hodkinson PD, Tsakirides C, Reeve N, Gallagher L, Green ND, Woods DR. A Four-Way Comparison of Cardiac Function with Normobaric Normoxia, Normobaric Hypoxia, Hypobaric Hypoxia and Genuine High Altitude. PLoS One 2016;11(4):e0152868

 

Boos CJ, Mellor A, O'Hara JP, Tsakirides C, Woods DR. The Effects of Sex on Cardiopulmonary Responses to Acute Normobaric Hypoxia. High Alt Med Biol 2016;17(2):108-15

 

Boos CJ, Woods DR, Varias A, Biscocho S, Heseltine P, Mellor AJ. High Altitude and Acute Mountain Sickness and Changes in Circulating Endothelin-1, Interleukin-6, and Interleukin-17a.High Alt Med Biol. 2016 Mar;17(1):25-31.

​

Mellor AJ, Boos CJ, et al. Copeptin and arginine vasopressin at high altitude: relationship to plasma osmolality and perceived exertion. Eur J Appl Physiol. 2015;115(1):91-98. doi:10.1007/s00421-014-2994-7

​

Mellor AJ, Woods DR, O'Hara J, …Boos C. Rating of perceived exertion and acute mountain sickness during a high-altitude trek. Aviat Space Environ Med 2014; 85:1214-6.

 

Mellor A, Boos C et al. Cardiac Biomarkers at High Altitude. High Alt Med Biol 2014; 15(4):452-8.

 

Boos CJ, Holdsworth DA, Hall DP, Mellor A, O'Hara J, Woods DR. Comparison of two methods of assessing total body water at sea level and increasing high altitude. Clin Physiol Funct Imaging 2014; 34(6):478-84

 

Boos CJ, Holdsworth DA, Woods DR, Green K, Naylor J, Mellor A. Cardiac biomarkers and high altitude pulmonary oedema. Int J Cardiol 2013; 167:e65-6.

​

Boos CJ, Hodkinson PD, Mellor A, Green NP, Bradley D, Greaves K, Woods DR.  The Effects of Prolonged Acute Hypobaric Hypoxia on Novel Measures of Biventricular Performance. Echocardiography 2013; 30:534-41.

​

Boos CJ, Hodkinson P, Mellor A, Green NP and Woods DR. The effects of acute hypobaric hypoxia on arterial stiffness and endothelial function and its relationship to changes in pulmonary artery pressure and left ventricular diastolic function. High Alt Med Biol 2012; 13:105-11

 

Woods DR, Mellor A, Begley J, Boos C.  Brain natriuretic peptide and NT-proBNP levels reflect pulmonary artery systolic pressure in trekkers at high altitude. Physiol Res 2013; 20; 62:597-603.

​

Woods DR, Mellor A, Begley J, Stacey….. Boos C. Brain natriuretic peptide and NT-proBNP levels reflect pulmonary artery systolic pressure in trekkers at high altitude Physiol Res 2013;62:597-603.

​

Mellor A, Boos C, et al. Neutrophil gelatinase-associated lipocalin: its response to hypoxia and association with acute mountain sickness. Dis Markers. 2013; 35:537-42.

​

Woods DR, Begley J, Stacey M, Smith C, Boos CJ, ….Mellor A.  Severe acute mountain sickness, brain natriuretic peptide and NT-proBNP in humans. Acta Physiol (Oxf) 2012; 205:349-55.

​

Boos CJ, Yasmin Jamil, Mirae Park, Wayland Moy, Vikram Khanna, AC Timperley, S Bristow and Professor S Sharma. The Prevalence of Electrocardiographic Abnormalities in Medically Screened UK Military Aircrew? Aviat Space Environ Med 2012; 83:1055-9.

​

Boos CJ, Simms P, Morris FR, Fertout M. The use of exercise and dietary supplements among British soldiers in Afghanistan.  J R Army Med Corps 2011 Sep; 157(3):229-32.

​

Michaelides M, Kaines A, Hamilton RD....Boos CJ et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular oedema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117:1078-1086.

 

Boos CJ, Wheble GA, Campbell MJ, Tabner KC, Woods DR. The use of dietary and exercise supplements in a deployed military population. J R Army Med Corps 2010; 156:32-6.

 

Idriss NK, Lip GY, Balakrishnan B, Jaumdally R, Boos CJ, Blann AD. Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor. Thromb Haemost 2010; 13;104.

 

Boos CJ, Balakrishnan B, Blann AD, Lip GY. The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis. J Thromb Haemost 2008 6:1841-50.

 

Boos CJ, Balakrishnan B and Lip GY. The effects of exercise stress testing on soluble E-selectin, von Willebrand factor, and circulating endothelial cells as indices of endothelial damage/dysfunction. Ann Med 2008; 40:66-73.

 

Boos CJ, Balakrishnan B, Jessani S, Blann AD, Lip GY. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction. Chest 2007; 132:1920-6.

 

Boos CJ, Balakrishnan B and Lip GY. The effects of coronary artery disease severity on time-dependent changes in platelet activation indices in stored whole blood. J Thromb Thrombolysis 2008;25:135-40.

 

Goon PK, Watson T, Shantsila E, Boos CJ et al. Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells. J Thromb Haemost 2007; 5:870-2.

 

Boos CJ, Soor SK, Kang D et al. Relationship between Circulating Endothelial Cells and the predicted risk of Cardiovascular Events in Acute Coronary Syndromes. European Heart Journal 2007; 28:1092-101.

 

Boos CJ, Beevers G, Lip GYH. Assessment of platelet activation indices using the ADVIATM120 amongst ‘high risk’ patients with hypertension. Ann Med 2007; 39:72-8.

 

Boos CJ, Lip GY and Jilma B. Endotoxemia, inflammation, and atrial fibrillation. Am J Cardiol 2007; 100:986-8.

 

Boos CJ, Lane DA, Karpha M et al. Circulating endothelial cells, arterial stiffness and cardiovascular risk stratification in hypertension. Chest 2007; 132:1540-7.

 

Boos CJ, Jaumdally RJ, Macfayden RJ et al. Circulating endothelial cells and von Willebrand factor as indices of endothelial damage/dysfunction in coronary artery disease: a comparison of central vs peripheral levels and effects of coronary angioplasty. J Thromb Haemost 2007; 5:630-2.

 

Goon PKY, Boos CJ, Stonelake PS et al. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads:  a methodological comparison. Thromb Haemostas 2006; 96:45-52.

 

Boos CJ, Mayr FB, Lip GY et al. Endotoxemia enhances circulating endothelial cells in humans. J Thromb Haemost 2006;4:2509-11.

 

Boos CJ, Lane DA, Kang D et al. Temporal and venepuncture-related decline in Circulating Endothelial Cell capture from mixed venous blood. J Thromb Thrombolysis 2006; 22:125-31.

 

 

Boos CJ, Gough S, Wheater M et al. The Effects of Transvenous Pacing on Cardiac Troponin Release. Pacing Clinical Electrophysiology 2004; 27:1264-1268.

 

 

Boos C, Wilbourne G, Clarke E et al. Higher energy monophasic direct current cardioversion for persistent atrial fibrillation: is it time to start at 360 joules? Annals of Non Invasive Electrocardiology 2003; 8:121-127.

 

Boos C, Ritzema J and More R. Short burst oral Amiodarone improves cardioversion success rates for patients in persistent atrial fibrillation. Heart 2004 2004; 90:1063-4.

 

Boos C and Croft A. Smoking rates in the staff of a military field hospital before and after wartime deployment. J R Soc Med 2004; 97:20-22.

 

Bailey MS, Boos CJ, Vautier G et al. Gastroenteritis outbreak in British troops, Iraq. Emerg Infect Dis 2005;11:1625-8.

 

 

Review Articles                                  

 

Lane DA, Boos CJ, Lip GY.  Atrial fibrillation (chronic).BMJ Clin Evid 2015; 2015-0217.

 

Brown LAE, Boos CJ. Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant. Int J Cardiol. 2017 Jan 15;227:863-868.

 

Boos CJ, Brown L. Anticoagulation in atrial fibrillation and chronic heart failure: the risk and drug of choice. Curr Opin Cardiol. 2016 Mar;31(2):229-34.

 

Cox AT, Cameron-Smith M, Folkes F, Sharma S, Boos C.  Screening for cardiac disease in potential recruits to the British Army. J R Army Med Corps 2015; 161:173-9.

 

Cox AT, Ayalew Y, White S, Boos CJ, Haworth K, Ray S.  Pericarditis and pericardial effusions in the military patient. J R Army Med Corps 2015; 161:268-74.

 

Cox AT, White S, Ayalew Y, Boos C, Haworth K, McKenna WJ.  Myocarditis and the military patient.  J R Army Med Corps 2015; 161:275-82.

 

Holdsworth DA, Cox AT, Boos C, Hardman R, Sharma S.  Cardiomyopathies and the Armed Forces. J R Army Med Corps 2015; 161(3):259-67.

 

Parsons IT, Cox AT, Mollan IA, Boos CJ.  Managing the military patient with syncope.

J R Army Med Corps.2015; 161:180-6.

 

Cox AT, Boos CJ, Sharma S. The Hearts of Heroes: The epidemiology of cardiac disease in the UK Armed Forces. J R Army Med Corps 2015; 161:169-72.

 

Boos CJ, Nam M, Camm AJ. Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev 2013; 19:391-401.

​

Woods DR, Boos C, Roberts PR. Cardiac arrhythmias at high altitude. J R Army Med Corps 2011; 157:59-62.

​

Lane DA, Apostolakis S, Boos CJ, Lip GY. Atrial fibrillation (chronic). Clin Evid (Online). 2011 Nov 10;2011. pii: 0217.

Narayana SK, Woods DR, Boos CJ. Management of amiodarone-related thyroid problems. Ther Adv Endocrinol Metab. 2011; 2:115-26.

​

Boos CJ, Cox AT. Cardiology.  J R Army Med Corps 2010; 156:172-5.

 

Lip GYH, Boos CJ. Antithrombotic treatment in atrial fibrillation. Postgrad Med J 2008; 84:252-8.

 

Boos CJ, Lane D and Lip GYH. Management of chronic atrial fibrillation. Clin Evidence (BMJ) 2007

 

Kakar P, Boos CJ and Lip GY. Management of atrial fibrillation. Vasc Health Risk Manag 2007; 3:109-16.

 

Boos CJ, Blann AD and Lip GY. Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Methods Mol Med 2007; 139:211-24.

 

Boos CJ, Blann AD, Lip GY. Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Methods Mol Med 2007; 39:211.

 

Boos CJ and Lip GY. Assessment of mean platelet volume in coronary artery disease - What does it mean? Thromb Res 2007; 120:11-3.

 

Goon PKY, Boos CJ and Lip GYH. Circulating endothelial cells and circulating endothelial progenitor cells in cancer. Neoplasia 2006; 8:79-88.

 

Boos CJ, Lip GY and Blann AD. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol 2006; 48:1538-47.

 

Boos CJ and Lip GYH. Blood clotting, inflammation, and thrombosis in cardiovascular events: perspectives. Front Biosc 2006; 11:328-36.

 

Boos CJ and Lip GYH. Is hypertension an inflammatory process. Curr Pharm Des 2006; 12:1623-1635.

 

Boos CJ and Lip GYH. Antithrombotic treatment in atrial fibrillation. Heart 2006; 92:155-61.

 

Boos CJ, Anderson RA and Lip GYH. Is atrial fibrillation an inflammatory disorder?

Eur Heart J 2006; 27:136-49.

 

Boos CJ and Lip GYH. Ximelagatran for stroke prevention in atrial fibrillation. Expert Rev Cardiovasc Ther 2005; 3:551-63.               

 

Goon PKY, Boos CJ and Lip GYH. Circulating Endothelial Cells: markers of vascular dysfunction. Clin Lab 2005; 51:531-8.

 

Boos CJ and Lip GYH. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 2005; 19:855-9

 

Goon PKY, Boos CJ and Lip GYH. Circulating endothelial cells in malignant disease. Future Oncology 2005; 1:813-20.

 

Boos CJ, Hinton A and Lip GYH. Ximelagatran; A clinical perspective. Eur J Intern Med 2005; 16:267-78.

 

Boos CJ and More R.  Anticoagulation for non-valvular atrial fibrillation - towards a new beginning with ximelagatran. Curr Control Trials Cardiovasc Med 2004; 5:3.

 

Boos CJ and Lip GYK. Novel therapies for the prevention of stroke. Expert Opin Investig Drugs 2004; 13:1615-30.

 

Boos CJ.  ACE Cardiovascular protection. More HOPE for EUROPA Med Sci Monit 2004; 10:SR23-28.

 

Boos C and More R. Rate control in atrial fibrillation. Clinical Medicine 2003; 3:291-2.   

 

Boos C and More R. Management of Persistent Atrial Fibrillation in the Older Patient. Geriatric Medicine 2003; 33:51-7.

 

Carlsson J and Boos C. Confounding factors in rate versus rhythm control trials in patients with atrial fibrillation: Lessons from the Strategies of Treatment of Atrial Fibrillation (STAF) Pilot Study. Card Electrophysiol Rev 2003; 7:122-6.

 

Boos C, Carlsson J and More R.  Rate or rhythm control in persistent atrial fibrillation? Quarterly Journal of Medicine 2003; 96:881-92.

 

 

Editorials

 

Boos CJ. Exercise capacity and septal myectomy in hypertrophic cardiomyopthy: Predicting clinical response. Eur J Prev Cardiol. 2020;27(10):1064-1065. doi:10.1177/2047487319894874    

 

Boos CJ. Infection and atrial fibrillation: inflammation begets AF. Eur Heart J. 2020;41(10):1120-1122. doi:10.1093/eurheartj/ehz953

​

Boos CJ, Sharma S. Sudden cardiac death in the British military: should all service recruits undergo ECG screening? J R Army Med Corps. 2011; 157:187-90.

 

Boos CJ and Lip GY. Inflammation and atrial fibrillation: cause or effect? Heart 2008; 94:133-4.

 

Boos CJ and Lip GY.  Platelet activation and cardiovascular outcomes in acute coronary syndromes. J Thromb Haemost 2006; 4:2542-3.

 

Boos CJ, Lip GY. C-reactive protein and lone atrial fibrillation: potential confounders.

Am J Cardiol 2006;98:991-2.

 

Boos CJ and Lip GYH. Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events.  Arterioscler Thromb Vasc Biol 2006; 26:e18.      

                               

Boos CJ, Goon PKY and Lip GYH. The endothelium, inflammation and coagulation in sepsis. Clin Pharmacol Ther 2006; 79:20-2.

 

Boos CJ, Goon PK and Lip GY. Endothelial progenitor cells in the vascular pathophysiology of hypertension: arterial stiffness, ageing and more. J Hum Hypertens 2006; 20:475-7.

 

Boos CJ and Lip GYH. Ximelagatran – a eulogy. Throm Res 2006; 118:301-4.

 

Lane DA, Boos CJ and Lip GYH. Anticoagulation control with vitamin K antagonists - how well are we doing? Chest 2006; 129:1122-4.

 

Boos CJ and Lip GYH. Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction? Am J Hypertens 2006; 9:511-2.

 

Boos CJ and Lip GYH. Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension? J Hum Hypertens 2005; 19:511-3.

 

Boos CJ and Lip GYH. The role of inflammation in atrial fibrillation.  Int J Clin Pract 2005; 59:870-2.

 

Lip GYH and Boos CJ. Ethnic differences in arterial responses, inflammation, and metabolic profiles: possible insights into ethnic differences in cardiovascular disease and stroke. Arterioscler Thromb Vasc Biol 2005; 25:2240-2.

 

Boos CJ and Dawes M. ACE cardiovascular protection: EUROPA versus HOPE. Cardiovascular Drugs and Therapy 2004; 18:179-180.

 

Boos C, Carlsson J and More R. Persistent atrial fibrillation - rate control or rhythm control? Rate control is not inferior to rhythm control. BMJ 2003; 326:1411-12.

                                                               

 

​

​

Claridge S, Chakrabarti A, Greaves K, Boos CJ. Successful use of Trastuzumab following cardiac resynchronisation therapy. Int J Cardiol. 2013; 166(2):e33-4.

 

White SH, Dickson S, Colman T, Hoque F, Boos CJ. Back pain in a Bangladeshi worker in Iraq. J R Army Med Corps 2010; 156:44-6.

 

Boos CJ, White SH, Bland SA, McAllister PD. Dietary Supplements and Military Operations: Caution is Advised. J R Army Med Corps 2010; 156:41-3.

 

Boos CJ, Cox AT. Cardiology. J R Army Med Corps. 2010 Sep;156(3):172-5.

 

Boos CJ, Bentall AJ, Marshall HJ. A technique to overcome high defibrillation thresholds for an implantable cardioverter defibrillator Cardiol Young 2009; 19:291.

 

Boos CJ, Martin U, Cherry RC, Marshall HJ. Dangerous Sandwiches. Lancet 2008; 372:2164.

 

Boos CJ, Khan Y and Throne S. An unusual case of misdiagnosed ventricular tachycardia. Emerg Med J 2008; 5:173-4.

 

Boos CJ, Calver AL, Moors A et al.  Uterine artery embolization in the setting of acute sub-massive pulmonary embolism. BJOG 2005; 112:1440-2.

 

Boos CJ, Daneshvar C, Hinton A et al. An unusual case of chronic meningitis. BMC Fam Pract 2004;5:21.

​

Boos C, Dawes M, Jones et al. Danazol treatment and acute myocardial infarction. Journal of Obstetrics and Gynaecology 2003; 23:327-8.

 

​

Boos C, Rumsby G and Matfin G. Multiple tumors associated with late onset congenital adrenal hyperplasia due to aberrant splicing of adrenal 21-hydroxylase gene. Endocrine Practice 2003; 8:470-3.

 

Boos C, Allen P, More R et al. Fever six weeks after trauma. Journal of the Royal Society of Medicine 2003;96:187-8.

 

CJ Boos, P Flies, M Dawes et al.  Shortness of breath in an obese young man. Journal of Academic Physician Assistants 2003; 3:2.

 

 

Letters

 

Boos C, Burford C.The changing landscape of anticoagulation and atrial fibrillation.

Clin Med 2012; 12:96-7.

 

Boos CJ, Treveil I. Use of transoesophageal echocardiography during the peri-operative period for trauma patients: sprinting before we can walk or run!  J R Army Med Corps 2011; 157:255; author reply 255-6.

 

Boos CJ. Iron deficiency: an ominous sign in patients with systolic chronic heart failure Eur Heart J 2010 31(15).

 

Gorman S, Boos C. Ivabradine in heart failure: what about digoxin? Lancet 2008; 372:2113.Boos

CJ and Marshall HJ. Risk of thromboembolism and bleeding with short-term interruption of anticoagulant therapy. Arch Intern Med 2008; 168:1932.

 

Boos CJ and Lip GYH. The role of inflammation in atrial fibrillation:  Increasing evidence in support of a novel concept. In J Clin Pract 2006; 60:497-8.

 

Boos CJ and Lip GYH. Is atrial fibrillation an inflammatory disorder?  Responses and clarifications.  European Heart Journal 2006; 27:136-49.

 

Boos CJ, Lip GYH. Prevention of Atrial fibrillation by Angiotensin-Converting-Enzyme inhibitors and Angiotensin II receptor blockers: some pathophysiological insights.                                                             

J Am Coll Cardio 2006; 47:889-90.

 

Boos CJ and Lip GYH. Assessment of hemostatic risk factors in predicting arterial thrombotic events.  ATVB 2006; 26:e18.

 

Boos CJ, Lip GYH. Biomarkers in atrial fibrillation; further observations on biologic plausibility, cause and effect Journal of Thrombosis and Thrombolysis 2005; 20:189-90.

 

Boos CJ, Goon PKY and Lip GYH.  Circulating endothelial progenitor cells. N Engl J Med 2005; 353:2613.

 

Boos CJ. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25:1761.

 

Boos CJ. Present treatment options for atrial fibrillation. Postgrad Med J 2003;79:604.

 

Boos CJ. Atrial fibrillation.  Cleve Clin J Med 2003; 70:998.

 

Boos CJ. Oral anticoagulation and stroke in atrial fibrillation. N Engl J Med 2003; 349:2360-1.

 

Boos CJ. The EUROPA trial. Lancet 2003; 362:1935.

 

​

Book Chapters            

 

Boos CJ and Lip GYH. Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells. Vascular Biology Protocols 2006.

 

Boos CJ and Lip GYH. Insights into novel anticoagulants.  Thrombosis Molecular Mechanisms of Disease 2006.